No Data
No Data
BioCryst Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $12
BioCryst Pharma Analyst Ratings
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $15
Express News | BioCryst Pharmaceuticals Inc : Needham Raises Target Price to $15 From $14
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18